聯系電話:512-67626747 聯系郵箱:eegene215@qq.com
合作廠商登彔/蘇州翊準基因科技有限公司

2010.Lung Cancer. 2010 Apr.68(1)51-7. Epub 2009 Jul 8.

發布時間:2016-10-28 ??? 閱讀數:

 Activating mutation of the K-ras gene was one of the earliest discoveries of genetic alterations in lung cancer. Moreover, K-ras somatic mutations might be suggested for predicting resistance to molecular antibodies targeting the epidermal growth factor receptor (EGFR). However, activated K-ras mutant detection methods are limited to traditional techniques. The techniques are complicated and are used only in tissue samples, which are limited for clinical applications. In a previous study, we established a low-cost, convenient, and easy technique for detecting activated K-ras in a small number of circulating tumor cells by the colorimetric membrane array method (CLMA). However, the sensitivity still needs further improvement. The aim of this study is to develop a new platform with chemiluminescence as reporter and weighted values of target genes on the chip in order to achieve a more sensitive, easier to read, and more accurate platform-weighted chemiluminecent membrane array (WCHMA). In advance, we collected 209 peripheral blood samples of non-small cell lung cancer (NSCLC) from patients to evaluate clinical K-ras activation detection using Activating KRAS Detection Chip both conducted by CLMA and WCHMA. Results show 71 specimens with K-ras mutation, of which 59 were identified as positive through CLMA and 66 were positive through WCHMA. After statistical analysis, the sensitivity of CLMA was found to be 83% and the specificity was 96%. On the other hand, the sensitivity of WCHMA increased to 93% and the specificity remained at 94%. Results of the detection limitation of peripheral blood on two platforms are: 3cancer cells/cm(3) blood using WCHMA, which is better than 5cancer cells/cm(3) blood using CLMA. Further analysis on the correlation between the test results and clinical pathological features shows that the mean score obtained using WCHMA is significantly correlated to TNM stage, tumor size, and metastasis.



上一篇: 2009.Fooyin J Health Sci 2009 Nov.1(2)72-80_automatic chipb
下一篇: 2010.Ann Surg Oncol 2010 Feb 17.624-33_WCLMAl

  • 蘇州翊準基因科技
    中國江蘇省蘇州市工業園區新平街388號B幢B-203(騰飛創新園塔樓B-203)
    電話:86-512-67626747
    傳真:86-512-67626747
    QQ:2957745965

Copyright © 2016 蘇州翊準基因科技有限公司 版權所有 蘇ICP備17013352號

伊人影院蕉久影院在线_伊人影院蕉久影院在线99_伊人影院蕉久草院在线